Vasomedical Inc. (VASO) Reports A Q3 Loss of $0.01
VASO Hot Sheet
Financial Fact:- diluted (in shares): 116.99M
Today's EPS Names:
TARO, BRLI, TLB, More
Vasomedical Inc. (Nasdaq: VASO) reports a Q3 loss of $0.01 vs. loss of $0.03 for Q3 2005. Revenues were $2.8 million vs. $3.0 million for Q3 2005.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Tsakos Energy Navigation Ltd. (TNP) Posts Narrower than Expected Q1 Loss
- Jiayuan.com (DATE) Reports In-Line Q1 EPS of 5c; Guides Q2 Revs
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
